BTIG analyst Julian Harrison maintained a Buy rating on Aura Biosciences Inc (AURA – Research Report) yesterday and set a price target of $38.00. The company’s shares closed yesterday at $11.84.
Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, CymaBay Therapeutics, and Outlook Therapeutics. According to TipRanks, Harrison has an average return of 24.8% and a 65.15% success rate on recommended stocks.
Currently, the analyst consensus on Aura Biosciences Inc is a Strong Buy with an average price target of $30.67, which is a 159.04% upside from current levels. In a report released on May 12, JMP Securities also reiterated a Buy rating on the stock with a $24.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
AURA market cap is currently $465.7M and has a P/E ratio of -6.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.
